<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074602</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8008-301</org_study_id>
    <nct_id>NCT05074602</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Parallel Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis (RVVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In&#xD;
      Subjects With Recurrent Vulvovaginal Candidiasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-Blind, active controlled, parallel groups, Multicenter Phase III Clinical Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with one or more culture-verified VVC episodes during the study.</measure>
    <time_frame>50 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with resolved VVC episode (clinical signs and symptoms score of &lt; 3) during induction phase</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with 2 culture-verified VVC episodes during the study.</measure>
    <time_frame>week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with ≥ 3 culture-verified VVC episodes during the study.</measure>
    <time_frame>week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with one or more culture-verified VVC episodes during the maintenance phase and follow-up phase.</measure>
    <time_frame>Week 3 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of a culture-verified VVC episode during the maintenance phase and follow-up phase.</measure>
    <time_frame>Week 3 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least one positive culture for Candida species during the maintenance phase and follow-up phase</measure>
    <time_frame>Week 3 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects receiving rescue treatment during the maintenance phase and follow-up phase.</measure>
    <time_frame>Week 3 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with clinical cure (defined as the absence of all signs and symptoms of VVC) at the end of induction phase .</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with mycological cure (defined as vaginal swab culture negative for growth of Candida species) at the end of induction phase.</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with therapeutic cure (clinical cure plus mycological cure) at the end of induction phase.</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with therapeutic cure, clinical cure, and mycological cure during the maintenance phase.</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with one or more culture-verified VVC episode during the maintenance phase</measure>
    <time_frame>Week 3 through Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least one positive culture for Candida species during the maintenance phase</measure>
    <time_frame>Week 3 through Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with one or more culture-verified VVC episode during the maintenance phase</measure>
    <time_frame>Week 3 through Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least one positive culture for Candida species during the maintenance phase</measure>
    <time_frame>Week 3 through Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with one or more culture-verified VVC episodes during the follow-up phase.</measure>
    <time_frame>Week 27 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least one positive culture for Candida species during the follow-up phase</measure>
    <time_frame>Week 27 through Week 50</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>SHR8008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR8008</intervention_name>
    <description>Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral</description>
    <arm_group_label>SHR8008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral</description>
    <arm_group_label>Fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females, ≥18 and ≤75 years old.&#xD;
&#xD;
          2. Have a history of RVVC at screening.&#xD;
&#xD;
          3. Suitable for oral therapy and able to swallow capsules intact.&#xD;
&#xD;
          4. Subjects of childbearing potential must use highly effective contraceptive measures&#xD;
             throughout the study.&#xD;
&#xD;
          5. Willing to sign the informed consent form to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of concomitant vulvovaginitis caused by other pathogens.&#xD;
&#xD;
          2. Have a history of cervical cancer, or &quot;cervical intraepithelial neoplasia or&#xD;
             malignancy&quot; or &quot;atypical squamous cells of undetermined significance (ASCUS)&quot; as&#xD;
             indicated by Pap test or other tests reported within 1 year before screening (not&#xD;
             applicable to subjects with a history of total hysterectomy).&#xD;
&#xD;
          3. Any condition that, in the opinion of the investigator, could impact drug absorption,&#xD;
             distribution, or elimination.&#xD;
&#xD;
          4. Moderate to severe hepatic and/or renal disorders.&#xD;
&#xD;
          5. Significant laboratory abnormality at screening.&#xD;
&#xD;
          6. QTc interval greater than 470 ms or other clinically significant ECG abnormality at&#xD;
             screening.&#xD;
&#xD;
          7. Have received systemic or vulvovaginal antifungal drugs, antibacterials,&#xD;
             antitrichomonal, CYP3A4 substrates or inducers or inhibitors, and vulvovaginal&#xD;
             corticosteroids within 7 days prior to randomization.&#xD;
&#xD;
          8. Have received any estrogen replacement therapy or vaginal topical products.&#xD;
&#xD;
          9. Have received systemic corticosteroid therapy within 30 days or systemic&#xD;
             immunosuppressant therapy within 90 days prior to randomization;&#xD;
&#xD;
         10. Have planned surgery or other medical procedures that may impact compliance with the&#xD;
             protocol;&#xD;
&#xD;
         11. Known history of hypersensitivity or intolerance to azole antifungal drugs.&#xD;
&#xD;
         12. History of narcotic or drug abuse or alcoholism, or any other medical, psychiatric or&#xD;
             social condition that in the investigator's opinion could preclude compliance with the&#xD;
             protocol.&#xD;
&#xD;
         13. Women who are pregnant or lactating, or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
         14. Have received VT-1161 study medication in a previous study or received any&#xD;
             investigational medicinal product (IMP) in a clinical study within 5 half-lives of&#xD;
             that IMP prior to screening (if the half-life is unknown, 60 days prior to screening);&#xD;
&#xD;
         15. other conditions unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Cao, M.D</last_name>
    <phone>+0518-81220121</phone>
    <email>yong.cao@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinghe Lang, Bachelor</last_name>
      <phone>+86-10-69156699</phone>
      <email>langjh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

